Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60 -1.08% 55.00 53.20 55.00 55.00 53.00 55.00 1,396,534 16:14:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 135

Futura Medical Share Discussion Threads

Showing 17226 to 17250 of 20875 messages
Chat Pages: Latest  691  690  689  688  687  686  685  684  683  682  681  680  Older
DateSubjectAuthorDiscuss
11/9/2019
12:43
Doesn't the timing of the announcement that "a company (that) has been established and funded to specifically exploit the therapeutic potential of Cannabis" coming a day before the results raise an eyebrow?
glavey
11/9/2019
12:36
Wouldn't it be sensible to try a raise now given the (ahem)'elevated' s/p. "...to complete the second Phase 3 study (FM59) which the Group intends to commence during 2020, assuming that the results of FM57 are positive." That's funny, wasn't someone, back in the summer, selling the view that a successful product was just months away?
glavey
11/9/2019
12:25
Watch that short :-0
ragnarr
11/9/2019
12:23
"Most patients have elected to continue into the open-label, Phase 3, safety stage in which all patients are on the highest dose of MED2005." "That is very encouraging as they are unlikely to want to continue if they did not see benefits with med2005." Or it could mean that many did not see much / any benefit from the (unspecified) doses they received so wanted to try the maximum.
glavey
11/9/2019
12:09
i sold out.. too much risk of placing at the wrong level now... with Barder at the helm... he has done so many rinse repeat cash raising cycles that I'm now wary... doesn't help that he has hardly any stock himself (most of which he got in the confetti placing for his mates at Lombard..)STRONG SELL
pjj71
11/9/2019
10:58
Yes, unless you know what the breakdown across the arms was of those continuing into the extension, the 80% figure doesn't mean much. At most only around a fifth of them will have already had the maximum dose, so one can reasonably assume that most men in the extension study are there because it's the only way to be certain they've tried the highest dose.
supernumerary
11/9/2019
09:28
As the study was blind,it means all patients. Including the ones on the placebo then.
glavey
11/9/2019
09:21
Proactive investorsFutura Medical on track with lead drugThe update in erectile dysfunction treatment MED2005 was provided alongside interim resultsFutura Medical PLC - The gel has a number of potential advantages over the current array of pillsFutura Medical PLC (LON:FUM) chief executive James Barder said the company's team is speaking to key opinion leaders in the field of erectile dysfunction ahead of publishing headline data on MED2005 later this year.The company's drug candidate is a fast-acting gel that eliminates some of the common side-effects of the current pill-based treatments.Safety, dosing and efficacy are currently being assessed as part of European phase III clinical trial.In an update alongside the company's interim results, Barder said most of the men taking part in the double-blind study had elected to continue into the open-label safety stage during which all patients are on the highest dose of MED2005.The gel is one of a number of products being developed by Futura, whose technology transfers drugs through the skin barrier.It is partnered to take a pain and inflammation product to the market called TPR100 and is currently in communication with the UK regulator to clear up queries around it. It should have a response for the MHRA by the first quarter of next year, investors were told.It has also teamed up to develop its technology to deliver CBD, the non-psychoactive element of cannabis that is linked with pain relief as well as being used to combat stress and anxiety.The financial revealed the company had £5.63mln as at the end of June, while it picked up a £1.36mln research and development credit in August.As is common for company's at this formative stage of their development, Futura was loss-making - to the tune of £4.46mln.
ragnarr
11/9/2019
09:09
Asit Biotech (ASIT.BR) Market cap €24 M / Cash €10 Million / Phase 3 readout in December for their immunotherapy treatment for grass pollen (€500 Million peak sales potential)Unknown stock = Potential 10+ BAGGER GEM ...........GLTA Successful Pollen Season Confirms ASIT biotech On Track for Phase III Results of gp-ASIT+™ in December 2019 hxxps://www.globenewswire.com/news-release/2019/09/05/1911325/0/en/Successful-Pollen-Season-Confirms-ASIT-biotech-On-Track-for-Phase-III-Results-of-gp-ASIT-in-December-2019.html
ih_116147
11/9/2019
08:56
Looks like a good buying opportunity to me No unexpected news Wish I had some spare cash!!!!
mikethebike4
11/9/2019
08:50
this might be the reason for the drop...but if they get a deal done as soon as the results for the 1st phase III trial then it won't happen.. also this share isn't for widow and orphans... Going Concern At the period end the Group held GBP5.63 million of cash with a further GBP1.36 million of R&D tax credit refund received after the period end, in August 2019. As has been previously discussed, the cash currently held by the Group will not be sufficient to complete the second Phase 3 study (FM59) which the Group intends to commence during 2020, assuming that the results of FM57 are positive. The Board is therefore exploring a number of funding options including non-dilutory and dilutory options and believe that the results of the FM57 trial will have a major impact on these funding options and the costs associated with them. Whilst there can be no guarantee that any of these opportunities will be successfully concluded, the Directors believe that it remains appropriate to prepare the financial statements on a going concern basis.
keifer derrin
11/9/2019
08:48
cash call is definitely on its way but not until headline phase III data so probably Jan2020
ragnarr
11/9/2019
08:46
i said earlier looks like cash is tight... maybe they are back to their old tricks and a confetti placing is on its way...
pjj71
11/9/2019
08:41
if it is a shakey shakey - it's a pretty big one....I guess the addage buy on the rumour sell on the news - is being played out today.....
keifer derrin
11/9/2019
08:36
Excellent RNS confirming that patients wanted to continue using it with maximum dosage, could not of asked for a better RNS.
tiananmen
11/9/2019
08:29
GAP at 25 - 26p... "Just Saying"
5oletrader
11/9/2019
08:27
shakey shakey
ragnarr
11/9/2019
08:23
A placing has always been on the cards to enable the next commercialisation stage but it will not be until the headline data for phase III is out.All indications are that the data will be very positive so expect share price to be in the 50s by then
ragnarr
11/9/2019
08:17
There been talk of a placing for ages. I can bet you it isnt in the 40s. Take the money and run for now - 5m wont last long at all.
phurley
11/9/2019
07:43
cheers J777J then it makes the RNS even better...guess we just have to sit around waiting for the results at the end of the year...(which will mean listening people moaning about the share price drifting...lol hahahaha)
keifer derrin
11/9/2019
07:39
As the study was blind,it means all patients. That is very encouraging as they are unlikely to want to continue if they did not see benefits with med2005.
j777j
11/9/2019
07:18
"Patient recruitment was completed in June 2019 and at the end of August over 500 patients had completed the 12 week double-blind phase of the study with 80% of these patients having elected to continue into the open label extension to study long term safety of the highest dose. " This is the best part of the RNS - but I have a question. The Phase III tests where using three different doses. Does this sentence mean that 80% of the patients of all the doses levels are carrying on testing the higher dose or just 80% of the patients on the higher dose....or am i over thinking it?
keifer derrin
11/9/2019
07:09
"Most patients have elected to continue into the open-label, Phase 3, safety stage in which all patients are on the highest dose of MED2005." Seems like good news as the patients presumably liked the effects of Med2005.
j777j
11/9/2019
07:06
looks like cash is going to be a problem with that burn-rate...
pjj71
10/9/2019
20:56
This whole CBD thing is going bonkers in the States. Usually vaped or taken sublingualy. Vaping getting tons of bad press lately and CBD under the tongue tastes really bad. So who knows? Idk that it can hurt anything. We got a little bump in share price plus have something new to talk about :)
tommyl1
Chat Pages: Latest  691  690  689  688  687  686  685  684  683  682  681  680  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 03:27:51